Ibuprofen API Market Size & Share 2024 – 2032

Ibuprofen API Market Size

Ibuprofen API Market was valued at USD 694.4 million in 2023 and is anticipated to grow at a CAGR of 3.7% between 2024 – 2032. The increasing prevalence of inflammatory diseases such as arthritis and rheumatoid arthritis has led to a rising demand for ibuprofen API, as it is widely used to alleviate pain and reduce inflammation.

Additionally, the growing geriatric population globally, which is more prone to such conditions, further fuels the demand for ibuprofen API. Moreover, the rising trend of self-medication, supported by the easy availability of over-the-counter ibuprofen products, is also a significant driver of market growth. Furthermore, the expanding pharmaceutical industry and the continual introduction of innovative formulations and combination products containing ibuprofen API are expected to contribute to market expansion in the coming years.
 

Ibuprofen API refers to the active pharmaceutical ingredient of the medication ibuprofen. Active pharmaceutical ingredients are the biologically active component responsible for the therapeutic effects of the drug. Ibuprofen API is widely used in various formulations such as tablets, capsules, and suspensions, and it is available both over the counter and by prescription.
 

Ibuprofen API Market Trends

• The increasing prevalence of pain conditions globally has emerged as a substantial growth driver for the market.
   
• Conditions such as arthritis, back pain, inflammatory disorders, and other chronic pain conditions are becoming common, increasing the demand for effective pain management drugs. For instance, as per the Global RA Network, 2021, more than 350 million people have arthritis globally. Similarly, based on data from the National Health Interview Survey (NHIS), during 2019 – 2021, an estimated 53.2 million adults in the U.S. were diagnosed with some form of arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia.
   
• Such high prevalence of pain disorders increases the demand for effective pain medications, thereby driving the ibuprofen API industry.
   
• Ibuprofen is a widely used nonsteroidal anti-inflammatory drug (NSAID) and is favored for its effectiveness in relieving mild to moderate pain, reducing inflammation, and lowering fever.
   
• The drug's popularity stems from its broad applicability across age groups and its relatively low incidence of side effects compared to other pain medications.
   
• Thus, as the global population continues to age and chronic diseases become more prevalent, the demand for ibuprofen API is expected to grow.
   

Ibuprofen API Market Analysis

Based on type, the market is segmented into standard ibuprofen and high potency ibuprofen. The high potency ibuprofen segment dominated the market is 2023 and accounted for USD 400.9 million.
 

• High potency ibuprofen commands a significant market share in the ibuprofen API industry due to its enhanced efficacy and dosage efficiency.
   
• Pharmaceutical companies prefer high potency ibuprofen because it allows for the formulation of lower-dose tablets or capsules, which are easier for patients to consume and can lead to improved patient compliance.
   
• Furthermore, the demand for high potency ibuprofen is driven by its cost-effectiveness in manufacturing and its ability to meet stringent quality standards, making it a preferred choice for many pharmaceutical manufacturers worldwide.
   

Learn more about the key segments shaping this market

Download Free PDF

 Based on application, the ibuprofen API market is segmented into arthritis, headache, fever, dental pain, and other applications. The arthritis segment dominated the market with 31.9% of market share in 2023.
 

• High market share of arthritis can be attributed to the widespread prevalence of arthritis-related conditions, such as osteoarthritis and rheumatoid arthritis, which affect millions of people worldwide.
   
• For instance, as per the U.S. Department of Health & Human Services, rheumatoid arthritis (RA) affects around 1% of the world population, with approximately 1.3 million adults in the U.S. suffering from RA.
   
• This rising incidence of arthritis, coupled with the increasing awareness and accessibility of ibuprofen-based medications, has led to a significant portion of the market being attributed to arthritis treatments.
   

Based on end-use, the ibuprofen API industry is categorized into pharmaceutical & biopharmaceutical companies and CDMO's. The pharmaceutical & biopharmaceutical companies segment dominated the market in 2023 and is predicted to grow at CAGR of 3.4% over the forecast period.
 

• Ibuprofen is widely used for its analgesic, antipyretic, and anti-inflammatory properties, making it a key ingredient in many over the counter and prescription medications.
   
• Pharmaceutical and biopharmaceutical companies utilize ibuprofen API to formulate several medications for pain relief, fever reduction, and inflammation management.
   
• The consistent demand for ibuprofen-based medications, coupled with the extensive research and development activities undertaken by pharmaceutical & biopharmaceutical companies make them key end-users in the market.
   

North America ibuprofen API market is anticipated to grow at a CAGR of 3.5% over the forecast years to reach USD 379.5 million by 2032.
 

• The region benefits from a well-established pharmaceutical industry, advanced healthcare infrastructure, and high levels of healthcare expenditure.
   
• Additionally, the prevalence of conditions such as arthritis, which often require ibuprofen for pain relief, contributes to the market's growth.
   
• Moreover, the presence of key players and continuous research and development activities in the region support the market's expansion, making North America a dominant player in the market.
   

U.S. ibuprofen API industry was valued at USD 255.8 million in 2023.
 

• The country's robust pharmaceutical industry, coupled with a high incidence of inflammatory conditions, contributes to its strong position in this market.
   
• For instance, as per the CDC, every 1 in 4 adults in the U.S. has arthritis. Further, it is estimated that by 2040, 78 million U.S. adults will have arthritis.
   
• Further, the country's well-established regulatory framework and stringent quality standards also play a crucial role, ensuring the reliability and safety of ibuprofen API produced in the U.S. These factors combined make the U.S. a dominant player in the global market.
   

Germany has emerged as a key player in the global market for ibuprofen API, showcasing high growth potential.
 

• The country's robust pharmaceutical industry, advanced research and development capabilities, and a strong regulatory framework contribute significantly to the market growth.
   
• Germany's strategic geographical location within Europe also enhances its position as a hub for pharmaceutical manufacturing and distribution.
   
• Additionally, the increasing prevalence of chronic diseases and the growing demand for pain management therapies are driving the demand for ibuprofen APIs in the region.
   

India ibuprofen API market is anticipated to witness lucrative growth between 2024 – 2032.
 

• The increasing prevalence of chronic diseases and the rising demand for pain management medications are driving the growth of the ibuprofen API industry in India.
   
• Additionally, the country's strong pharmaceutical manufacturing base, skilled workforce, and cost-effective production capabilities further enhances the market growth.
   

Ibuprofen API Market Share 

The ibuprofen API industry is fragmented in nature characterized by the presence of several companies. The key market players are focused on developing improved formulations to obtain a competitive edge in the market. These players are constantly engaged in growth strategies such as partnerships and collaborations, and distribution strategies to enhance their market reach.
 

Ibuprofen API Market Companies

Prominent players operating in the ibuprofen API industry include:

• BASF Corporation
• Dr. Reddy's Laboratories Ltd.
• Granules India Limited
• IOL Chemicals and Pharmaceuticals Limited
• Octavius Pharma Pvt. Ltd.
• SI Group, Inc.
• Solara Active Pharma Sciences Limited
• Strides Pharma Science Limited
• Rochem International Inc.
• Teva Pharmaceutical Industries Ltd.
   

Ibuprofen API Industry News

• In November 2022, Solara Active Pharma Sciences Limited received `Certificate of Suitability' (CEP) approval from European Directorate for the Quality of Medicines (EDQM) to manufacture ibuprofen from its new multipurpose API manufacturing facility at Vishakhapatnam, Andhra Pradesh. This key approval helped the company to boost its ibuprofen production capacity.
   
• In August 2018, SI Group announced plans to expand ibuprofen capacity in its Orangeburg, South Carolina facility in the U.S. This helped the company to increase its production capacity by 25% and thereby cater to increased market demand.
   

The ibuprofen API market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Standard ibuprofen
• High potency ibuprofen

Market, By Application

• Headache
• Arthritis
• Fever
• Dental pain
• Other applications

Market, By End-use

• Pharmaceutical & biopharmaceutical companies
• CDMO's

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa